Chambré beds down as chair of CRT
This article was originally published in Scrip
Cancer Research Technology, the commercial arm of Cancer Research UK, has appointed Peter Chambré chair of the board. Mr Chambré is currently chairman of Xellia Pharmaceuticals and 7TM Pharma and a non-executive director of BTG and Spectris. He previously served as chief executive of Cambridge Antibody Technology Group and succeeds Melanie Lee who was CRT's chair from 2003.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.